852329-66-9

Basic information

• Product Name: Dutogliptin
• Synonyms: Dutogliptin;[(2R)-1-[[(3R)-3-Pyrrolidinylamino]acetyl]-2-pyrrolidinyl]-boronic acid;((R)-1-(((R)-pyrrolidin-3-yl)glycyl)pyrrolidin-2-yl)boronic acid;Boronic acid, B-[(2R)-1-[2-[(3R)-3-pyrrolidinylamino]acetyl]-2-pyrrolidinyl]-
• CAS NO: 852329-66-9
• Molecular Formula: C₁₀H₂₀BN₃O₃
• Molecular Weight: 241.0951
• Mol File: 852329-66-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 494.6±55.0 °C(Predicted)
• Appearance: /
• Density: 1.24±0.1 g/cm3(Predicted)
• PKA: 9.71±0.20(Predicted)
• CAS DataBase Reference: Dutogliptin(CAS DataBase Reference)
• NIST Chemistry Reference: Dutogliptin(852329-66-9)
• EPA Substance Registry System: Dutogliptin(852329-66-9)

Safety Data

• Hazardous Substances Data: 852329-66-9(Hazardous Substances Data)

Usage

Description

Dutogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, a chemical compound used in the management of type 2 diabetes. It functions by inhibiting the DPP-4 enzyme, which leads to an increase in incretin hormone levels, stimulating insulin release and reducing liver glucose production, thereby regulating blood sugar levels and improving glycemic control.

Uses

Used in Pharmaceutical Industry:
Dutogliptin is used as an oral medication for the treatment of type 2 diabetes. It helps to regulate blood sugar levels and improve glycemic control by inhibiting the DPP-4 enzyme, leading to increased incretin hormone levels and enhanced insulin release.
Used in Diabetes Management:
Dutogliptin is used as an adjunct therapy in combination with other diabetes medications to manage blood sugar levels more effectively. Its mechanism of action complements other treatments, providing a comprehensive approach to diabetes management.
Note: Dutogliptin is still in the investigational stage and has not yet been approved for clinical use.

Upstream product

• 923566-03-4 (2R)-1-{2-[(3R)-pyrrolidinylamino]-acetyl}-pyrrolidine-2-boronic acid (1S,2S,3R,5S)-pinanediol ester 
• 1056211-06-3 3-(R)-(benzyloxycarbonyl-carboxymethyl-amino)-pyrrolidine-1-carboxylic acid benzyl ester 

Downstream Products

• 890402-81-0 dutogliptin-L-tartrate 

Relevant articles and documents

Pyrrolidine ester dipeptidyl peptidase inhibitors and its pharmaceutical composition

The invention relates to pyrrolidine ester (boronate ester) DDP - IV inhibitors, dipeptidyl peptidase - IV participation in diseases such as diabetes in particular 2 type diabetes, tumor or other treatment and prevention of disease in a useful role. This invention relates to pharmaceutical compositions comprising these compounds and in the prevention or treatment of dipeptidyl peptidase - IV in these diseases.

HETEROCYCLIC BORONIC ACID COMPOUNDS

Dipeptidyl peptidase IV (DPP-IV)-inhibiting compounds are provided that have formula I: wherein n is 1 to 3; X is CH2; S; O; CF2 or C (CH3)2; Z is H; halogen; hydroxyl; (C1-6)alkoxy; (C1-12)alkyl; (C3-12)cycloalkyl; phenyl; or heteroaryl; where the phenyl and heteroaryl groups are optionally mono- or independently plurisubstituted with R7; optionally, X together with an adjacent ring carbon and Z form a fused cyclopropyl; and optionally, one of the bonds in the ring containing X is a double bond; and CriRii, R1, R1, R3, R4 and R5 are as described herein. Methods for preparing these compounds, and methods for treating diabetes, especially Type II diabetes, and other related diseases are described using the compounds of formula I in pharmaceutical compositions which contain these compounds. Pharmaceutical compositions which contain combinations of these compounds with other antidiabetic agents are also described herein.